NCT06454188View on ClinicalTrials.gov

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Psoriatic ArthritisSpondyloarthritis, Axial
Interventions
DRUG

Upadacitinib 15 MG [Rinvoq]

15mg tablet once per day.

DRUG

Placebo

15mg tablet once per day.

Trial Locations (4)

77377

RECRUITING

DM Clinical Research, Tomball

97239

RECRUITING

Oregon Health and Science University, Portland

K1H 7W9

NOT_YET_RECRUITING

The Ottawa Hospital Research Institute, Ottawa

G1V 3M7

RECRUITING

Groupe de Recherche en Maladies Osseuses (G.R.M.O.) Inc., Québec

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

CARE ARTHRITIS LTD.

INDUSTRY